Application of HIV-1 Complementation System to Screen the Anti-AIDS Agents That Targets the Late Stage of HIV-1 Replication Cycle

바이러스 생활환의 후기 단계에 작용하는 항AIDS제의 탐색을 위한 HIV-1 Complementation System의 응용

  • Ryu, Ji-Yoon (Department of Genetic Engineering, Division of Biological Sciences, College of Natural Sciences, Hallym University) ;
  • Choi, Soo-Young (Department of Genetic Engineering, Division of Biological Sciences, College of Natural Sciences, Hallym University) ;
  • Kim, Yung-Hi (Department of Pharmacology, College of Medicine, Hallym University) ;
  • Park, Jin-Seu (Department of Genetic Engineering, Division of Biological Sciences, College of Natural Sciences, Hallym University)
  • 류지윤 (한림대학교 자연과학대학 유전공학과) ;
  • 최수영 (한림대학교 자연과학대학 유전공학과) ;
  • 김영희 (한림대학교 의과대학 약리학교실) ;
  • 박진서 (한림대학교 자연과학대학 유전공학과)
  • Published : 2000.09.30

Abstract

Continuous efforts are being made to find effective therapeutic agents against HIV-1, the causative agents of AIDS. In this study, we developed a cell-based assay system employing a trans-complementation for production of recombinant viruses which are capable of undergoing one round of replication in CD4+ T cells. This assay system was tested for ability to screen the agents that act at late stage of HIV-1 life cycle. The effect of a protease inhibitor on the trans-complementation assay was assessed. Recombinant HIV-1 viruses were prepared from a trans-complementation in the presence of various concentrations of protease inhibitor. Inhibition of single round infection of these recombinant viruses by protease inhibitor was observed to be a dose-dependent manner. Inhibitory effects of a protease inhibitor on HIV-1 Gag polyprotein processing by HIV-1 protease was detected at concentrations of the protease inhibitor compatible with inhibition of virus infection, confirming that the corresponding step was involved in the inhibitory mechanism of this compound. Together, these results provide evidence that a cell-based assay system established in this study can be used to screen the agents that target the late stage of HIV-1 life cycle.

Keywords